Madrid, Spain, November 25 (ots/PRNewswire) - - Aplidin(R) now in Phase II trials in both solid and haematological cancers PharmaMar, the biopharmaceutical company specialising in cancer therapy, today announces that its marine derived anti-tumour agent, Aplidin(R), has commenced Phase II clinical trials in haematological malignancies, including studies in Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) ...
London, November 23 (ots/PRNewswire) - - Agfa, Vital Images, and Viatronix to Use Medicsight Software Medicsight Inc.'s (OTC Bulletin Board: MSHT) majority owned subsidiary, Medicsight PLC ("Medicsight"), announced today that it has signed letters of intent with Agfa-Gevaert N.V. and Viatronix and a ...
Seattle, November 19 (ots/PRNewswire) - Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato) today announced that it is responding to inquiries from the U.S. Attorney for the Western District of Washington in connection with previously disclosed promotional practices for TRISENOX. CTI is fully cooperating with the U.S. Attorney in this matter. About Cell Therapeutics, Inc. Headquartered in Seattle, CTI ...
Madrid, November 19 (ots/PRNewswire) - PharmaMar announced today that Aplidin(R) (1), its second marine-derived compound in clinical development, was granted orphan drug status by the European Commission for the treatment of multiple myeloma (MM) following adoption of a positive opinion by the Committee for ...
Glasgow, Scotland, November 18 (ots/PRNewswire) - - RESIST-2 Data Demonstrate Efficacy in Treatment-Experienced Patient Population New tipranavir pivotal Phase III data show that a statistically significant higher percentage of treatment-experienced HIV-positive patients taking tipranavir therapy achieved treatment response versus those taking other ...
Princeton, New Jersey, November 17 (ots/PRNewswire) - Clearview Projects, Inc. announced today that Jan Wolpert has joined the company as President & CEO. Most recently, Jan was the president, founder and principal owner of Wolpert Associates, Inc., a strategic management consulting firm specializing in corporate development matters. With offices in both New Jersey and California, Clearview Projects provides ...
Montreal, November 17 (ots/PRNewswire) - - Exceptional exposure for Nstein Technologies Nstein Technologies Inc. (TSX-V: EIN), an emerging leader in new Business Intelligence (BI) solutions, received international exposure today at the United Nations at the official launch of the enhanced version of the ...
PEROS SYSTEMS TECHNOLOGIES INC
ST- NICOLAS, Canada, November 16 (ots/PRNewswire) - Under a cooperative research agreement signed in December of 2003 the USDA-ARS and PerOs Systems Technologies Inc, conducted tests combining PerOs' oral drug delivery technology, Oralject(TM), with the USDA-ARS' vaccine developed against the streptococcal ...
London, November 16 (ots/PRNewswire) - New research published today in the European Journal of Cancer (EJC) (1) indicates that an overwhelming 78 per cent of healthy premenopausal women would prefer goserelin ('Zoladex (TM)') therapy to chemotherapy if they were to develop oestrogen-receptor positive (ER+) early ...
London, November 15 (ots/PRNewswire) - - Optimal Adjuvant Therapy Should Now Include an AI Such as 'Arimidex' (anastrozole) in Order to Reduce the Risk of Tumour Recurrence Today, the American Society of Clinical Oncology (ASCO) Technology Assessment Panel announced a fundamental change to its internationally recognised guidance on the use of ...
Turku, Finland, November 12 (ots/PRNewswire) - - The Partnership Agreement on the First Indication (Pathological Gambling) Could be Valued at up to USD 13.2 Million Plus Royalties - Somaxon to Initiate a Phase III Clinical Development Program in Pathological Gambling Biotie Therapies Corp. and Somaxon ...
New Orleans, November 10 (ots/PRNewswire) - - Analysis of 30 Adverse Event Risk Factors Offers New Insights for Patient Care Data presented today at the 2004 American Heart Association Scientific Sessions further documented the low incidence of Major Adverse Cardiac Events (MACE) and stent thrombosis ...
Vienna, Austria, November 2 (ots/PRNewswire) - - Significant Advances in the Clinical Development of Yondelis(TM) and Aplidin(R) PharmaMar, the biopharmaceutical company specialising in cancer therapy, presented new data from its two lead drugs, Yondelis(TM) and Aplidin(R), at the 29th European Society for Medical Oncology Congress (ESMO) held in Vienna, Austria from 29 October to 2 November 2004. Data ...
London, Ontario, November 1 (ots/PRNewswire) - In this week's issue of the Lancet Neurology, glatiramer acetate, known as Copaxone(R), was subjected to an independent review. The systematic review, called a Cochrane Review, performed by Dr. Luca Munari and colleagues, challenges the claims of benefit from previous industry-based publications. A convincing ...
Washington, November 1 (ots/PRNewswire) - New data from a pivotal Phase 3 study (RESIST-1) demonstrate that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed protease inhibitors (PIs). Treatment response in this study ...
Basel, Switzerland (ots/PRNewswire) - - New Treatment Option the First to Help Postmenopausal Women With Early Breast Cancer Remain Cancer-Free Following Adjuvant Tamoxifen Therapy Femara(R) (letrozole) is the first therapy approved by the U.S. Food and Drug Administration (FDA) for the extended adjuvant treatment of postmenopausal women with early breast ...
Shire Pharmaceuticals Group Plc
St Louis, Missouri (ots/PRNewswire) - Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced that long-term treatment with FOSRENOL(R) (lanthanum carbonate) for up to five years, shows no deterioration in bone health according to new data presented today for the first time at the ...
Vienna, Austria (ots/PRNewswire) - - Medical experts and patients call for early diagnosis to improve chances of cure According to leading oncologists, speaking today at the European Society for Medical Oncology, findings from the MOSAIC study represent a significant step forward in providing colon ...
Madrid (ots/PRNewswire) - PharmaMar today announced that Kahalalide F (KF), its marine-origin compound, has entered into Phase II trials for the treatment of patients with severe psoriasis. KF is currently undergoing Phase II clinical trials in various tumours: melanoma, non-small lung cancer and hepatocarcinoma. During the Phase I clinical trials on ...
Madrid (ots/PRNewswire) - The Zeltia Group (ZEL.MC) today reported financial results for the third quarter and the nine months ended September 30, 2004. Q3 Highlights Financial: - Group sales up 6.3% to Euro 63.7million (Euro 59.9 million 9M03) - Losses before interest and tax narrowed significantly to Euro 2.3 million (Euro 5.5 million 9M03) - R&D down by 28.9% to Euro 27.8 million reflecting a ...
Prague, Czech Republic (ots/PRNewswire) - - Patients call for better standards of care People with psoriasis are still being treated as social outcasts according to the results of a new international survey announced on World Psoriasis Day. This has led for calls from a leading patient advocate, Lars ...
Basel, Switzerland (ots/PRNewswire) - - New M3 selective receptor antagonist treatment for overactive bladder Novartis Pharma AG announced today that Emselex(R) (darifenacin hydrobromide), 7.5 mg and 15 mg, has been granted Marketing Authorization by the European Commission for the treatment of overactive bladder (OAB) in all 25 European member states as ...
Espoo, Finland (ots/PRNewswire) - - Parkinson's Patients who Require the Start of Levodopa Therapy may be Eligible to Participate in This Study Orion Pharma and Novartis announced that they are launching STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation). This major study in Parkinson's disease (PD) ...
Basel, Switzerland (ots/PRNewswire) - - Parkinson's Patients Who Require the Start of Levodopa Therapy May Be Eligible to Participate in This Study Novartis and Orion Pharma announced that they are launching STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation). This major study in Parkinson's disease ...
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for tipranavir. Simultaneously the documentation was submitted to the FDA. Tipranavir is a non-peptidic protease inhibitor (NPPI) for ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its innovative cancer drug, Avastin has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP). The CHMP has recommended that Avastin (bevacizumab) in combination with intravenous ...
Basel, Switzerland (ots/PRNewswire) - Key figures First nine months Nine months 2004 Nine months 2003 % Change USD m % of sales USD m % of sales USD lc[1] Sales 20 669 18 134 14 9 Pharmaceutical 11 641 ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today the appointment of Patrice R. Debregeas to its board of directors. As Chairman, CEO and President of Ethypharm S.A, the leading drug delivery company in Europe, Mr. Debregeas brings extensive international experience in the pharmaceutical ...
Buenos Aires, Argentina (ots/PRNewswire) - -- Additional Analysis Shows Couples Agree Cialis Improves Erectile Function in Men with ED and Increases Satisfaction with Sexual Experience -- An international study conducted in 21 countries showed that 82 percent of men with ED who were treated with 20 mg ...
Copenhagen, Denmark (ots/PRNewswire) - Tamas Bartfai, Ph.D., is the director of the Harold L. Dorris Neurological Research Center at The Scripps Research Institute, La Jolla, CA. In addition, he holds the Harold L. Dorris Chair in Neuroscience. Professor Bartfai is former head of central nervous system research at Hoffman-La Roche where he served as Senior Vice ...